drugset / Trial / NCT01620476

Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers

NCT01620476

Phase 1 Completed 24 enrolled Novo Nordisk A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in Japan. The aim of this trial is to assess the safety and tolerability of liraglutide in healthy Japanese male subjects.

Timeline

Start
2003-09
Primary completion
2004-03
Completion
2004-03

Publications

  • Results Kageyama S, Hirao K, Shimizu A, Matsumura Y, Zdravkovic M, Rasmussen MF, Irie S. Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long-acting human GLP-1 analogue - Phase 1 studies in Japanese healthy subjects with type 2 diabetes. Endocrinology and Diabetology 2007; 24 (6): 95-104

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 5 ug/kg Subcutaneous
Subject Liraglutide Peptide 10 ug/kg Subcutaneous
Subject Liraglutide Peptide 15 ug/kg Subcutaneous

Indications